15,619 Shares in Agilon Health, Inc. $AGL Bought by 111 Capital

111 Capital bought a new position in shares of Agilon Health, Inc. (NYSE:AGL) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 15,619 shares of the company’s stock, valued at approximately $36,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. grew its holdings in shares of Agilon Health by 6.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,060,333 shares of the company’s stock valued at $21,911,000 after acquiring an additional 311,158 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Agilon Health by 8.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 4,939,576 shares of the company’s stock worth $21,388,000 after purchasing an additional 398,027 shares during the period. Nuveen LLC bought a new position in Agilon Health during the first quarter worth about $17,242,000. CenterBook Partners LP bought a new position in Agilon Health during the first quarter worth about $8,315,000. Finally, Amundi grew its holdings in Agilon Health by 49.2% during the first quarter. Amundi now owns 1,484,709 shares of the company’s stock worth $5,939,000 after purchasing an additional 489,414 shares during the period.

Wall Street Analyst Weigh In

AGL has been the subject of several research reports. Barclays cut their price objective on shares of Agilon Health from $3.00 to $1.50 and set an “underweight” rating for the company in a research report on Wednesday, August 6th. Wells Fargo & Company lowered their price objective on shares of Agilon Health from $5.00 to $1.50 and set an “overweight” rating for the company in a research report on Tuesday. Evercore ISI lowered their price objective on shares of Agilon Health from $5.00 to $3.00 and set an “in-line” rating for the company in a research report on Wednesday, July 9th. Benchmark lowered their price objective on shares of Agilon Health from $4.00 to $1.50 and set a “buy” rating for the company in a research report on Wednesday, August 6th. Finally, Robert W. Baird decreased their target price on shares of Agilon Health from $5.00 to $1.00 and set a “neutral” rating on the stock in a research note on Thursday, August 14th. Four equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $2.81.

Agilon Health Stock Down 4.9%

AGL stock opened at $1.07 on Wednesday. The firm has a market cap of $441.36 million, a price-to-earnings ratio of -1.38 and a beta of 0.07. Agilon Health, Inc. has a 12-month low of $0.71 and a 12-month high of $6.08. The company’s fifty day simple moving average is $1.18 and its 200 day simple moving average is $2.43.

Agilon Health (NYSE:AGL) last released its earnings results on Monday, August 4th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.14). The firm had revenue of $1.39 billion during the quarter, compared to analyst estimates of $1.47 billion. Agilon Health had a negative net margin of 5.35% and a negative return on equity of 66.76%. Agilon Health’s quarterly revenue was down 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.07) EPS. Research analysts expect that Agilon Health, Inc. will post -0.59 earnings per share for the current year.

Agilon Health Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.